197 related articles for article (PubMed ID: 32575424)
1. Molecular and Genomic Profiling of Lung Cancer in the Era of Precision Medicine: A Position Paper from the Italian Association of Thoracic Oncology (AIOT).
Normanno N; Barberis M; De Marinis F; Gridelli C; On The Behalf Of The Aiot Expert Panel
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32575424
[TBL] [Abstract][Full Text] [Related]
2. Molecular tests and target therapies in oncology: recommendations from the Italian workshop.
Pinto C; Biffoni M; Popoli P; Marchetti A; Marchetti P; Martini N; Normanno N
Future Oncol; 2021 Sep; 17(26):3529-3539. PubMed ID: 34254524
[TBL] [Abstract][Full Text] [Related]
3. The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer.
Nesline MK; Subbiah V; Previs RA; Strickland KC; Ko H; DePietro P; Biorn MD; Cooper M; Wu N; Conroy J; Pabla S; Zhang S; Wallen ZD; Sathyan P; Saini K; Eisenberg M; Caveney B; Severson EA; Ramkissoon S
Oncol Ther; 2024 Jun; 12(2):329-343. PubMed ID: 38502426
[TBL] [Abstract][Full Text] [Related]
4. Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer.
Signorovitch J; Zhou Z; Ryan J; Anhorn R; Chawla A
J Med Econ; 2019 Feb; 22(2):140-150. PubMed ID: 30430885
[TBL] [Abstract][Full Text] [Related]
5. The possibility of clinical sequencing in the management of cancer.
Kou T; Kanai M; Matsumoto S; Okuno Y; Muto M
Jpn J Clin Oncol; 2016 May; 46(5):399-406. PubMed ID: 26917600
[TBL] [Abstract][Full Text] [Related]
6. Current practice of genomic profiling of patients with advanced solid tumours in Italy: the Italian Register of Actionable Mutations (RATIONAL) study.
Normanno N; De Luca A; Abate RE; Morabito A; Milella M; Tabbò F; Curigliano G; Masini C; Marchetti P; Pruneri G; Guarneri V; Frassineti GL; Fasola G; Adamo V; Daniele B; Berardi R; Feroce F; Maiello E; Pinto C
Eur J Cancer; 2023 Jul; 187():174-184. PubMed ID: 37167765
[TBL] [Abstract][Full Text] [Related]
7. ASPiRATION: Australian observational cohort study of comprehensive genomic profiling in metastatic lung cancer tissue.
Mersiades AJ; Solomon BJ; Thomas DM; Lee CK; Cummins MM; Sebastian L; Ballinger ML; Collignon E; Turnbull OM; Yip S; Morton RL; Brown C; Wheeler PJ; Itchins M; Simes RJ; Pavlakis N
Future Oncol; 2024 Mar; 20(7):361-371. PubMed ID: 37767626
[TBL] [Abstract][Full Text] [Related]
8. The Challenges and Opportunities of the Implementation of Comprehensive Genomic Profiling in Everyday Clinical Practice with Non-Small Cell Lung Cancer: National Results from Croatia.
Čerina D; Krpina K; Jakopović M; Dedić Plavetić N; Seiwerth F; Tomić S; Radić J; Belac Lovasić I; Canjko I; Boban M; Samaržija M; Vrdoljak E
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444505
[TBL] [Abstract][Full Text] [Related]
9. First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities.
Matsubara J; Mukai K; Kondo T; Yoshioka M; Kage H; Oda K; Kudo R; Ikeda S; Ebi H; Muro K; Hayashi R; Tokudome N; Yamamoto N; Muto M
JAMA Netw Open; 2023 Jul; 6(7):e2323336. PubMed ID: 37459099
[TBL] [Abstract][Full Text] [Related]
10. Integrating comprehensive genomic sequencing of non-small cell lung cancer into a public healthcare system.
Perdrizet K; Stockley TL; Law JH; Smith A; Zhang T; Fernandes R; Shabir M; Sabatini P; Youssef NA; Ishu C; Li JJ; Tsao MS; Pal P; Cabanero M; Schwock J; Ko HM; Boerner S; Ruff H; Shepherd FA; Bradbury PA; Liu G; Sacher AG; Leighl NB
Cancer Treat Res Commun; 2022; 31():100534. PubMed ID: 35278845
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.
Suh JH; Johnson A; Albacker L; Wang K; Chmielecki J; Frampton G; Gay L; Elvin JA; Vergilio JA; Ali S; Miller VA; Stephens PJ; Ross JS
Oncologist; 2016 Jun; 21(6):684-91. PubMed ID: 27151654
[TBL] [Abstract][Full Text] [Related]
12. Clinical Utility and Benefits of Comprehensive Genomic Profiling in Cancer.
Tjota MY; Segal JP; Wang P
J Appl Lab Med; 2024 Jan; 9(1):76-91. PubMed ID: 38167763
[TBL] [Abstract][Full Text] [Related]
13. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
14. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
[TBL] [Abstract][Full Text] [Related]
15. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive genomic profiling for patients with chemotherapy-naïve advanced cancer.
Kondo T; Matsubara J; Quy PN; Fukuyama K; Nomura M; Funakoshi T; Doi K; Sakamori Y; Yoshioka M; Yokoyama A; Tamaoki M; Kou T; Hirohashi K; Yamada A; Yamamoto Y; Minamiguchi S; Nishigaki M; Yamada T; Kanai M; Matsumoto S; Muto M
Cancer Sci; 2021 Jan; 112(1):296-304. PubMed ID: 33007138
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive genomic profiling for non-small-cell lung cancer: health and budget impact.
Johnston KM; Sheffield BS; Yip S; Lakzadeh P; Qian C; Nam J
Curr Oncol; 2020 Dec; 27(6):e569-e577. PubMed ID: 33380872
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive genomic profiling for oncological advancements by precision medicine.
Pankiw M; Brezden-Masley C; Charames GS
Med Oncol; 2023 Nov; 41(1):1. PubMed ID: 37993657
[TBL] [Abstract][Full Text] [Related]
19. Liquid biopsy comprehensive genomic profiling of lung cancer in the Italian population: A real-world experience.
Porta C; Pradelli L; Sicari E; Castellani S; Sivakumar S; Sokol E; Montesion M; Wieland T; Rambichler J; Minari R; Tiseo M
Lung Cancer; 2023 Nov; 185():107359. PubMed ID: 37703610
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
Ali SM; Hensing T; Schrock AB; Allen J; Sanford E; Gowen K; Kulkarni A; He J; Suh JH; Lipson D; Elvin JA; Yelensky R; Chalmers Z; Chmielecki J; Peled N; Klempner SJ; Firozvi K; Frampton GM; Molina JR; Menon S; Brahmer JR; MacMahon H; Nowak J; Ou SH; Zauderer M; Ladanyi M; Zakowski M; Fischbach N; Ross JS; Stephens PJ; Miller VA; Wakelee H; Ganesan S; Salgia R
Oncologist; 2016 Jun; 21(6):762-70. PubMed ID: 27245569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
